Company: NCEL
Filing Date: 2025-05-01
Form Type: NT 20-F
Source: 0001213900-25-038073
Chunk: 2

Company: NewcelX Ltd.
Filing Date: 2025-05-01
Form: NT 20-F
Chunk 2
---
 If answer is no, identify report(s). Yes ☒ No ☐ |

| (3) | Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? Yes ☐ No ☒ |

If so, attach an explanation of the
anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results
cannot be made.

<div align='center'>2

NLS PHARMCEUTICS LTD.

(Name of Registrant as Specified in Charter)</div>

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.

| Date | May 1, 2025 |     | By: | /s/ Alexander Zwyer     |
|:-----|:------------|:----|:----|:------------------------|
|      |             |     |     | Alexander Zwyer         |
|      |             |     |     | Chief Executive Officer |

<div align='center'>3</div>